Age on the GLP-1 label: 12+, 18+, and why the number is product-specific

One drug class, several age stories

“GLP-1 age limit” is a search phrase, not a single FDA number. The class includes daily and weekly injections and, for semaglutide, a tablet. Each product’s Indication and Pediatric Use sections control who was studied and who is included on the label.

This page summarizes those sections for commonly searched brands. It is educational, not an eligibility quiz, and not an offer of pediatric care. Beema Health’s public program pages describe adult medical weight management. Do not submit a child’s health information into a marketing form.

Products with a 12-and-older obesity indication

Wegovy injection is indicated, with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction in pediatric patients aged 12 years and older with obesity. The label cites a 68-week trial in adolescents whose BMI was at or above the 95th percentile for age and sex. Adverse reactions were generally similar to adults, with some events (including certain gallbladder and skin reactions) reported more often in the pediatric trial than in adults.

Saxenda (liraglutide 3 mg daily) is separately labeled for pediatric patients 12 years and older with body weight above 60 kg and obesity. Daily injections, GI effects, and the same boxed thyroid C-cell warning still apply. These pediatric indications do not mean every 12-year-old with a high BMI should start medication. Guidelines and specialists still emphasize family-based lifestyle care first for many youth.

Adult-only labels you should not stretch

Zepbound is indicated in adults for chronic weight management (and for obstructive sleep apnea in adults with obesity). Pediatric use has not been established. Mounjaro is indicated for adults with type 2 diabetes. Ozempic is indicated for adults with type 2 diabetes, with additional cardiovascular and kidney-related labeled uses in adults as described in its PI. Using those products in children for weight loss is not what their pediatric sections support.

Wegovy tablets are indicated in adults for weight reduction and certain cardiovascular-risk uses; pediatric effectiveness has not been established. Oral SNAC chemistry is not a junior version of the pen.

• Wegovy injection: pediatric obesity indication at 12+.
• Wegovy tablets: pediatric use not established.
• Zepbound: adults; pediatric use not established.
• Ozempic and Mounjaro: adult diabetes (and other adult) labels - not pediatric weight-loss indications.
• Saxenda: separate 12+ obesity indication with weight criteria.

Age does not waive the boxed warning

GLP-1 receptor agonists and tirzepatide carry a boxed warning about thyroid C-cell tumors in rodents and are contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2. That contraindication is not relaxed because someone is 14 or because someone is 70. See the thyroid article.

Pregnancy and lactation rules also sit outside “age limit” debates. Several products say to discontinue when pregnancy is recognized for weight-reduction use. Those are clinician conversations, not birthday-based checkboxes.

How clinicians actually use age

Age is a starting filter, then kidneys, other medicines, eating-disorder history, growth (in youth), sarcopenia (in older adults), and the person’s goals. Online quizzes that output “you qualify” from age and BMI skip the labeled contraindications and the physical exam or history a licensed clinician must do.

If you are reading this as a parent, ask a pediatric obesity or endocrinology clinician about labeled options, monitoring, and whether medicine is appropriate at all. If you are an adult comparing brands, use the product PI, not a class-wide age meme.

Frequently asked questions

Sources

1. [1] Wegovy (semaglutide) prescribing information. Novo Nordisk. Pediatric use for injection in ages 12 years and older with obesity; tablets not established in pediatrics.
2. [2] Zepbound (tirzepatide) prescribing information. Eli Lilly. Indication in adults; pediatric use not established.
3. [3] Ozempic (semaglutide) prescribing information. Novo Nordisk. Adult type 2 diabetes indication; pediatric use.
4. [4] Mounjaro (tirzepatide) prescribing information. Eli Lilly. Adult type 2 diabetes; pediatric use not established.
5. [5] Saxenda (liraglutide) prescribing information. Novo Nordisk. Pediatric patients 12 years and older with body weight above 60 kg and obesity.